AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

Chronic myeloid leukemia (CML) represents the first human malignancy successfully treated with a tyrosine kinase inhibitor (TKI; imatinib). However, early relapses and the emergence of imatinib-resistant disease are problematic. Evidence suggests that imatinib and other inhibitors may not effectivel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhou, Liang L., Zhao, Yun, Ringrose, Ashley, DeGeer, Donna, Kennah, Erin, Lin, Ann E.-J., Sheng, Guoqing, Li, Xiao-Jiang, Turhan, Ali, Jiang, Xiaoyan
Formato: Artigo
Idioma:Inglês
Publicado em: The Rockefeller University Press 2008
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2571939/
https://ncbi.nlm.nih.gov/pubmed/18936234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20072316
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados